Immunis.AI is a privately held immunogenomics company committed to making a global impact by empowering patients and their physicians with actionable information for disease detection and management.
Our patented approach leverages the power of the body’s own immune defense system, next-generation sequencing (NGS) technology and machine learning to provide unique insights into disease biology.
Our Intelligentia™ platform enhances early stage disease detection, at the point where disease-causing factors escape immune surveillance, when there is the best opportunity for cure. Applying our proprietary algorithms, we compare gene expression patterns from two types of immune cells isolated from the blood, normalizing the signal for a truly individualized assessment.
Our vision is to leverage our foundational work to deliver a screening assay that can simultaneously identify and distinguish between multiple diseases from a single blood draw.
Our mission is to deliver tests that improve early detection, risk stratification and assessment of therapeutic response, all in a minimally invasive manner.